Skip to main content
SpringerLink
Log in

Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

This review concerns the clinical impact of low-density lipoprotein (LDL) apheresis for patients with refractory hypercholesterolemia. We examine and provide examples of investigations that have demonstrated the clinical benefits of LDL apheresis. In addition to benefits derived from the stabilization or regression of arterial lesions, we highlight other possible mechanisms related to clinical improvement. We also discuss the potential advantages of lipid apheresis for the treatment of patient populations other than those characterized by severe hypercholesterolemia and premature coronary heart disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Seidel D: H.E.L.P. apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience. Artif Organs 1996, 20:303–310.

    PubMed  CAS  Google Scholar 

  2. Schuff-Werner P, Stolz K, Rexer H, et al.: Adverse reaction of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.). First results of an observational study on the H.E.L.P. system. 5th Heparin-induced Extracorporeal LDL-Precipitation (HELP) Meeting, November 18–19, 2000, Kassel and Melsungen, Germany.

  3. Cashin-Hemphill L, Noone M, Abbott JF, et al.: Low-density lipoprotein apheresis therapy during pregnancy. Am J Cardiol 2000, 86:1160.

    Article  PubMed  CAS  Google Scholar 

  4. Gordon BR: Incorporation of low-density lipoprotein apheresis into the treatment program of patients with severe hypercholesterolemia. Curr Athero Rep 2000, 2:308–313.

    CAS  Google Scholar 

  5. Mabuchi H, Koizumi J, Shimizu M, et al.: Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998, 82:1495–1489.

    Article  Google Scholar 

  6. Schuff-Werner P, Gohlke H, Bartmann U, et al., for the H.E.L.P. Study Group: The H.E.L.P.-LDL-Apheresis Multicenter Study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest 1994, 24:724–732.

    Article  PubMed  CAS  Google Scholar 

  7. Rubba P, Iannuzzi A, Postiglione A, et al.: Hemodynamic changes in the peripheral circulation after repeat low density lipoprotein apheresis in familial hypercholesterolemia. Circulation 1990, 81:610–616.

    PubMed  CAS  Google Scholar 

  8. Koga N, Watanabe K, Kurashige Y, et al.: Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients. J Intern Med 1999, 246:35–43.

    Article  PubMed  CAS  Google Scholar 

  9. Moriarty PM, Barth J, Gibson CA: LDL apheresis in the reduction of carotid intima-media thickness: a case study. Submitted for publication.

  10. Kroon AA, Aengevaeren WR, van der Werf T, et al.: LDL Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996, 93:1826–1833.

    PubMed  CAS  Google Scholar 

  11. Stone MC, Thorp JM: Plasma fibrinogen—a major coronary risk factor. J Royal Coll Gen Practitioners 1985, 35:565–569.

    CAS  Google Scholar 

  12. Harkness J: Measurement of plasma viscosity. In Clinical Aspects of Blood Viscosity and Cell Deformability. Edited by Lowe GD, Barbanei JC, Forbes CD. Berlin: Springer-Verlag; 1981:79–87.

    Google Scholar 

  13. Yarnell JW, Baker IA, Sweetnam PM, et al.: Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell Collaborative Heart Disease studies. Circulation 1991, 83:836–844.

    PubMed  CAS  Google Scholar 

  14. Koenig W, Homback V, Ernst E, et al.: Plasma viscosity as a cardiovascular risk factor. Circulation 1992, 86:1045.

    PubMed  CAS  Google Scholar 

  15. Resch KL, Ernst E, Matrai A, Paulsen HF: Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med 1992, 117:371–375.

    PubMed  CAS  Google Scholar 

  16. Pfefferkorn TK, Knuppel HP, Jaeger BR, et al.: Increased cerebral CO2 reactivity after heparin-mediated extracorporeal LDL precipitation (HELP) in patients with coronary heart disease and hyperlipidemia. Stroke 1999, 30:1802–1806.

    PubMed  CAS  Google Scholar 

  17. Stadler RW, Ibrahim SF, Lees RS. Peripheral vasoactivity in familial hypercholesterolemic subjects treated with heparin-induced extracorporeal LDL precipitation (HELP). Atherosclerosis 1997, 128:241–249.

    Article  PubMed  CAS  Google Scholar 

  18. Tamai O, Matsuoka H, Itabe H, et al.: Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997, 128:241–249.

    Google Scholar 

  19. Mellwig KP, Baller D, Gleichmann U, et al.: Improvement of coronary vasodilatation capacity through single LDL-apheresis. Atherosclerosis 1998, 139:173–178.

    Article  PubMed  CAS  Google Scholar 

  20. Austin MA, Breslow JL, Hennekens CH, et al.: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260:1917–1921.21.

    Article  PubMed  CAS  Google Scholar 

  21. Krauss RM: Heterogeneity of plasma low density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994, 5:339–349.

    Article  PubMed  CAS  Google Scholar 

  22. Superko HR: Did Grandma give you heart disease? The new battle against coronary artery disease. Am J Cardiol 1998; 82:34Q-46Q.

    Article  PubMed  CAS  Google Scholar 

  23. Watts GF, Mandalia S, Brunt JN, et al.: Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas’ Atherosclerosis Regression Study (STARS). Metabolism 1993, 42:1461–1467.

    Article  PubMed  CAS  Google Scholar 

  24. Schamberger BM, Geiss HC, Ritter MM, et al.: Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. J Lipid Res 2000, 41:727–733.

    PubMed  CAS  Google Scholar 

  25. Sato T, Takebayashi S, Kohchi K: Increased subendothelial infiltration of the coronary arteries with monocytes-macrophages in patients with unstable angina. Histological data on 14 autopsied patients. Atherosclerosis 1987, 68:191–197.

    Article  PubMed  CAS  Google Scholar 

  26. Lindahl B, Toss H, Siegbahn A, et al.: Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000, 343:1139–1147.

    Article  PubMed  CAS  Google Scholar 

  27. Ferreiros E, Boissonet C, Pizzaro R, et al.: Independent progrnostic value of elevated C-reactive protein in unstable angina. Circulation 1999, 100:1958–1963.

    PubMed  CAS  Google Scholar 

  28. Liuzzo G, Biasucci L, Gallimore J, et al.: Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol 1999, 34:1696–1703.

    Article  PubMed  CAS  Google Scholar 

  29. Lagrand WK, Visser CA, Hermens WT, et al.: C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999, 100:96–102.

    PubMed  CAS  Google Scholar 

  30. Torzewski J, Rist C, Mortensen RF, et al.: Deposition of C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent recruitment of monocytes in atherogenesis. American Heart Association Abstracts from Scientific Sessions, New Orleans, November 12–15, 2000.

  31. Pasceri V, Willerson J, Yeh E: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165–2168.

    PubMed  CAS  Google Scholar 

  32. Pulawski E, Mellwig KP, Schmidt HK, et al.: Effect of single LDL apheresis (H.E.L.P. Method) on the adhesion molecules sVCAM-1, sICAM-1 and P-selectin. Z Kardiol 1998, 87(Suppl 1):230.

    Google Scholar 

  33. Moriarty PM, Gibson CA, Shih J, Matias MS: C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Submitted for publication.

  34. Mattox D, Lyles A: Idiopathic sudden sensorineural hearing loss. Am J Otol 1989, 10:242–247.

    PubMed  CAS  Google Scholar 

  35. Suckfull M, Thiery J, Wimmer C, et al.: Hypercholesterolemia and hyperfibrinogenemia in sudden deafness. Laryngorhinootologie 1997, 76:453–457.

    PubMed  CAS  Google Scholar 

  36. Suckfull M, Wimmer C, Jager B, et al.: Heparin-induced extracorporeal low-density-lipoprotein precipitation (HELP) to improve the recovery of hearing in patients with sudden idiopathic hearing loss. Eur Arch Otorhinolaryn 2000, 257:59–61.

    Article  CAS  Google Scholar 

  37. Natanson C, Hoffman WD, Suffredini AF, et al.: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994, 120:771–783.

    PubMed  CAS  Google Scholar 

  38. Hoffmann JH, Hartl WH, Deppisch R, et al.: Hemofiltration in human sepsis: evidence for elimination of immuno-modulatory substances. Kidney Int 1995, 48:1563–1570.

    PubMed  CAS  Google Scholar 

  39. Reinke P: Plasmapheresis in the therapy of septic disease. Int J Artif Organs 1996, 19:127–128.

    PubMed  CAS  Google Scholar 

  40. Aoki H, Kodama M, Tani T, Hanasawa K: Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994, 167:412–417.

    Article  PubMed  CAS  Google Scholar 

  41. Weber C, Rajnoch C, Loth F, et al.: The microspheres based detoxification system (MDS). Artif Organs 1994, 17:595–602.

    CAS  Google Scholar 

  42. Jaber BL, Pereira BJ: Extracorporeal adsorbent-based strategies in sepsis. Am J Kidney Dis 1997, 30(5 Suppl 4):S44-S56.

    PubMed  CAS  Google Scholar 

  43. Samtleben W, Boos KS, Fraunberger P, et al.: HELP in gram negative refractory septic shock: first clinical experiences. Jpn J Apheresis 1997, 16:91–96.

    Google Scholar 

  44. Bengsch S, Boos KS, Samtelben W, et al.: Use of HELP for the treatment of sepsis: first results of a study on the use of an adsorption apheresis method for the removal of endotoxins from the plasma of patients with severe sepsis. 5th Heparin-induced Extracorporeal LDL-Precipitation (HELP) Meeting, November 18–19, 2000, Kassel and Melsungen, Germany.

  45. Mulec H, Johnsen SA, Wiklund O, Bjorck S: Cholesterol: a risk factor in diabetic nephropathy. Am J Kidney Dis 1993, 22:196–201.

    PubMed  CAS  Google Scholar 

  46. Gin H, Rigalleua V, Aparicio M: Lipids, protein intake, and diabetic nephropathy. Diabetes Metab 2000, 26(suppl 4):45–53.

    PubMed  CAS  Google Scholar 

  47. Krolewski AS, Warram JH, Christlieb R: Hypercholesterolemia: a determinant of renal function loss and death in IDDM patients with nephropathy. Kidney Int 1994, 45:S125-S131.

    CAS  Google Scholar 

  48. Nakao T, Yoshino M, Matsumoto H, et al.: Low-density lipoprotein apheresis retards the progression of hyperlipidemic overt diabetic nephropathy. Kidney Int 1999, 56(suppl 71):S206-S209.

    Article  Google Scholar 

  49. Kojima S, Ogi M, Yoshimata Y, et al.: Changes in bradykinin and prostaglandins plasma levels during dextran-sulfate low-density-lipoprotein apheresis. Int J Artif Org 1997, 20:178–183.

    CAS  Google Scholar 

  50. Gullestad L, Nordal KP, Forfang K, et al.: Post-transplant hyperlipidaemia: low-dose lovastatin lowers atherogenic lipids without plasma accumulation of lovastatin. J Intern Med 1997, 242:483–490.

    Article  PubMed  CAS  Google Scholar 

  51. Miller LW, Schlant RC, Kobashigawa JA, et al.: 24th Bethesda Conference: cardiac transplantation. Task Force 5: Complications. J Am Coll Cardiol 1993, 22:41–54.

    Article  PubMed  CAS  Google Scholar 

  52. Park JW, Merz M, Braun P: Regression of transplant coronary artery disease during chronic low-density lipoprotein apheresis. J Heart Lung Transplant 1997, 16:290–297.

    PubMed  CAS  Google Scholar 

  53. Weidner G, Connor SL, Hollis JF, Connor WE: Improvements in hostility and depression in relation to dietary change and cholesterol lowering: the family heart study. Ann Intern Med 1992, 17:820–823.

    Google Scholar 

  54. Glueck CH, Tieger M, Kunkel R, et al.: Hypocholesterolemia and affective disorders. Am J Med Sci 1994, 308:218–225.

    Article  PubMed  CAS  Google Scholar 

  55. Glueck CH, Kunkel R, Tieger M: Pathophysiologic relationships and linkage among triglycerides, hypocholesterolemia, and depression. In Lipids, Health, and Behavior. Edited by Hillbrand M, Spitz RT. Washington, DC: American Psychological Association; YEAR?:99–112.

  56. Jick H, Zomberg GL, Jick SS, et al.: Statins and the risk of dementia. Lancet 2000, 356:1627–1631.

    Article  PubMed  CAS  Google Scholar 

  57. Walzl M, Lechner H, Walzl B, Schied G: Improved neurological recovery of cerebral infarctions after plasmapheretic reduction of lipids and fibrinogen. Stroke 1993, 24:1447–1451.

    PubMed  CAS  Google Scholar 

  58. Moriarty PM, Ryan JJ, Gibson CA, Paolo AM: Cognitive and emotional functions after rapid cholesterol lowering by heparin-induced extracorporal LDL precipitation (HELP). 2000, manuscript in preparation.

  59. Schwartz GG, Olsson AG, Ezekowitz MD, et al.: The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial: effects of intensive atorvastatin treatment on early recurrent events after an acute coronary syndrome. Circulation 2000, 102:2672.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lipid, Atherosclerosis, and Metabolic Clinic, University of Kansas Medical Center, 1336 KU Hospital, 3901 Rainbow Boulevard, 66160-7374, Kansas City, KS, USA

    Patrick M. Moriarty MD

  2. University of Kansas School of Medicine, 4025 Wescoe Pavilion, 3901 Rainbow Boulevard, 66160-7376, Kansas City, KS, USA

    Cheryl A. Gibson PhD

Authors
  1. Patrick M. Moriarty MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cheryl A. Gibson PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moriarty, P.M., Gibson, C.A. Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses. Curr Atheroscler Rep 3, 156–162 (2001). https://doi.org/10.1007/s11883-001-0052-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-001-0052-5

Keywords

Search

Navigation